StocksMedium•7 October 2026•
1 min read
FDA Grants Two Breakthrough Therapy Designations to AbbVie's Temab-A
Key Facts
1The U.S. FDA granted two Breakthrough Therapy Designations for Temab-A in colorectal cancer and non-small cell lung cancer.
The U.S. FDA granted two Breakthrough Therapy Designations for AbbVie's Temab-A for the treatment of colorectal cancer and non-small cell lung cancer. PR Newswire reported that the designations are based on the potential of Temab-A as a next-generation c-Met-directed antibody-drug conjugate to address advanced solid tumors.
ABBV closed at $266.69 on October 6, 2026, with the stock reaching a day high of $268.86 and a low of $260.62 during that session. The FDA's decision follows clinical data evaluating the drug's efficacy in patients who have previously received standard treatments, supporting its development as a monotherapy and in combination with other therapies.